A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) is a phase 2 interventional study registered as NCT06833073 by Merck Sharp & Dohme LLC, with 308 participants planned, started 2025-03-11 and due to reach its primary completion in 2031-09-03. Interventions recorded: Intismeran autogene and BCG.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Intismeran autogene, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Shares Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.